which can be hypoxic, acidic and deficient in nutrients, may result in the metabolism of tumour cells and the neighbouring stromal cells, including myeloid cells (such as tumour-associated macrophages, dendritic cells and myeloid-derived suppressor cells) and lymphocytes (T cells and B cells) for remodelling, thus facilitating tumour survival, proliferation and metastasis. [2] [3] [4] The TME of HCC may involve multiple metabolic abnormalities, among which, abnormal lipid metabolism is a fairly new field that attracts wide attention over the past few years. Dysregulation of lipid metabolism, especially for the metabolism of fatty acid (FA) where the aberrantly activated oncogenic signalling pathways alter the lipid-metabolizing enzyme expression and activity, has increasingly been recognized as an important metabolic rewiring phenomenon in tumour cells ( Figure 1) and immunocytes, and it may also participate in HCC development and progression. 3 This review aims to examine the mechanism by which this dysregulation modelled HCC cells and neighbouring immunocytes and support HCC progression and to explore the way for therapeutically targeting the aberrant lipid metabolism to benefit the HCC patients.
| ALTERED LIPID ME TABOLIS M OF HEPATOCELLUL AR C ARCINOMA CELL S

| Aberrant lipid metabolism
Increasing evidence suggests that alterations in tumour lipid metabolism, including metabolite abundance and accumulation of lipid metabolic products, lead to tumour development as well as local immunosuppression in the TME. 5 For instance, a previous study illustrated that the deletion of 5-lipoxygenase in the TME promoted lung cancer progression and metastasis through regulating T-cell recruitment. 6 A recent study has analysed the global gene expression profile of HCC, which reveals that genes involved in the biosynthesis of fatty acids (FAs) are universally up-regulated in most HCC tissues compared with the noncancerous liver tissues. 7, 8 Typically, FAs function as the signalling molecules, energy sources, and the structural components of cell membrane, all of which are essential for cancer cell proliferation. 9 Normal cells preferentially utilize the circulating exogenous lipids, whereas cancer cells, including HCC cells, show a high de novo lipid synthesis rate, 10 suggesting FA accumulation in tumour cells. The roles of major lipogenic enzymes, such as stearoyl-CoA desaturase (SCD), fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), have been reported to participate in hepatocarcinogenesis. For instance, the genetic ablation of FASN, which is responsible for synthesizing palmitate (C16:0) from acetyl-CoA and malonyl-CoA in the presence of NADPH, completely suppresses the Akt-driven HCC development through inhibiting the Rictor/mammalian target of rapamycin complex2 (TORC2) signalling. 11 ACC, which converts acetyl-CoA to malonyl-CoA as the first rate-limiting step in de novo lipogenesis, has attracted wide attention as a therapeutic target for non-alcoholic steatohepatitis (NASH). Typically, ACC1, an isoform of ACC, has been reported by Wang Although reduced FAO has been reported in many cases, some
HCCs display a distinctly different metabolic phenotype characterized by a high β-oxidation rate. 8 Enhanced FAO, reduced glycolysis accompanied by the up-regulated expression of PPARα and CPT2 are observed in the β-catenin-activated HCCs derived from mice and humans ( Figure 2 ), suggesting that such tumours rely mainly on FAO to provide energy. 8, 9, 14 Typically, the β-catenin-activated HCCs carry an activating mutation in the CTNNB1, a gene that encodes β-catenin in the Wnt pathway, whose mutation is not uncommon (19.5%) in human HCC. [15] [16] [17] Inhibiting FAO by genetic and pharmacological approaches blocks the HCC development, which suggests that inhibiting FAO is a suitable therapeutic approach for the β-catenin-mutated HCC. 14 In addition, Iwamoto et al recently reported that HCC cells would rather utilize FAO for their survival under the hypoxic conditions induced by the antiangiogenic drugs. Their results further showed that the oxygen and nutrient depletion induced by antiangiogenic drugs changed the glucose-dependent metabolism to the lipid-dependent metabolism through enhancing free FA uptake and the subsequent FAO, thus stimulating cancer cell proliferation. This phenomenon was mediated by the hypoxia-induced increased phosphorylation of activated protein kinase (AMPK), which increased FAO via increasing the CPT-1 activity by inducing the inhibitory phosphorylation of ACC2. 18 Recently, Bidkhori et al 19 had identified three HCC subtypes named iHCC1, iHCC2, and iHCC3 and pointed out that tumours in iHCC1 had the highest FAO fluxes, whereas 75% iHCC2 tumours carried mutations in CTNNB1, with up-regulated expression of β-catenin target genes (like glutamine synthetase GLUL and glutamate transporter SLC1A2). Finally, iHCC3 tumours were associated with the highest fluxes in FA biosynthesis and a strong Warburg effect.
Noteworthily, iHCC1 is the tumour group with the highest survival rate, which displays a high inflammation response compared with that of iHCC2 and is potentially associated with type 2 diabetes and obesity. iHCC3 tumours lead to the lowest survival rate and multiple malignant tumour features, including hypoxic behaviour and epithelial-to-mesenchymal transition (EMT). Therefore, it is speculated in this study that HCC patients with elevated FAO levels may have better prognosis, which is associated with higher inflammatory and immune responses. In addition, HCC with β-catenin mutation may be affected by lipotoxicity in a lipid-rich environment. On the other hand, the expression of phosphorylated AMPK is negatively correlated with the Ki-67 level (a cell proliferation marker), tumour grade and tumour size in HCC, as mentioned above, thus indicating that the high FAO level mediated by AMPK may be considered as a favourable factor. 20 In summary, these observations uncover the distinct differences in lipid metabolism within HCC that stem from the high inter-tumour heterogeneity, which are associated with patient survival.
| The Role of sterol regulatory elementbinding protein 1 in regulating lipid metabolism and promoting hepatocarcinogenesis
Furthermore, differential expression of transcription factors (TFs) also serves as the critical element for regulating lipid metabolism. Among them, sterol regulatory element-binding protein 1 (SREBP-1), a crucial TF, greatly affects the downstream targeted lipid genes, especially for the downstream target genes in the cholesterol metabolism pathway, which is also a master regulator of SCD, ACC and FASN. 
SREBP-1 in HCC cells induces growth arrest and apoptosis, whereas
over-expressing SREBP-1 enhances cell proliferation, suggesting that SREBP-1 may be a therapeutic target for HCC. 9
| MicroRNAs affect the development of HCC and NAFLD by regulating the lipid metabolic enzymes via the metabolic-related transcription factors
Recent studies contribute to understanding microRNAs (miRNAs), which are a class of small non-coding RNAs that regulate gene ex- the degree of hepatic steatosis through inhibiting the expression of fatty acid binding protein 1 (FABP1), thus delaying the progression of non-alcoholic fatty liver disease (NAFLD), which is a major catalytic agent of HCC. 28, 29 On the other hand, miRNAs also exert crucial roles in regulating the lipid-metabolizing enzymes through the metabolic-related transcription factors. A variety of miRNAs, including miRNA-33a/b, miRNA-182, miRNA-96 and miRNA-24, have been identified to participate in regulating SREBPs. [30] [31] [32] MicroRNA-631 and microRNA-155 were reported to have a negative regulatory effect on LXRα, which played a key role in regulating FA metabolism by regulating SREBP1-c as well as the downstream targets involved in FA synthesis. 33, 34 Several miRNAs have been summarized in Table 1 .
| Uptake and transport of exogenous FAs in HCC
Although most cancer cells exhibit a metabolic shift towards lipogenesis and synthesize nearly all esterified FAs de novo, some tumours tend to "acquire" free FAs directly from the external environment. 35 External FAs are brought into the cell through a transport mechanism involving specialized enzymes and proteins such as FA translocase (FAT or CD36), fatty acid transport proteins FATP2 and FATP5, and members of FABP family (FABP1, FABP4 and FABP5), which are involved in FA uptake and transport in hepatic tissues as well as in HCC. 36, 37 Increased expression of CD36 leads to higher FA uptake in HCC, which is closely related to induction of the mesenchymal transition (EMT). 36 The EMT may also be promoted when the enhanced FA levels of HCC patients up-regulate inflammation-related oncogenic transcriptional factors (NF-κB, AP-1, STAT3 and HIF-1α), which activate Wnt and TGF-β signalling pathways. 36, 38, 39 Given that depletion of FASN has been reported to significantly suppress HCC development, 40 there is also a great demand for novel therapeutic targets involved in lipid uptake and transport. In mouse hepatocytes, adenovirus-mediated knockdown of FATP2 or genetic deletion of FATP5 has been reported to significantly decrease the rates of fatty acid uptake, 41, 42 which might have the potential to be new targets with regard to HCC. Taken together, more researches are needed to study more detailed mechanisms and verify the effect of deletion.
| Liver dysfunctions linked to HCC
Liver cancer displays a high incidence among people with chronic non-infectious liver diseases. Specifically, a non-esterified FAsrich condition may be a characteristic environment of obesity-and F I G U R E 2 Lipid metabolic reprogramming in β-catenin-activated HCC. Fatty acid β-oxidation (FAO) is activated to fuel HCC non-alcoholic steatohepatitis (NASH)-driven HCC ( Figure 3 ). 43, 44 Nonetheless, it remains to be further explored about how HCC cells survive and grow in such an environment. Research shows that in human steatohepatitic HCC (SH-HCC), the expression of carnitine palmitoyltransferase 2 (CPT2), which converts acylcarnitine back to acyl-CoA, is down-regulated; subsequently, the marked accumulation of acylcarnitine species is detected, suggesting that the serum acylcarnitine levels may serve as a biomarker of HCC. 45 More importantly, CPT2 down-regulation suppresses the FAO pathway and enables HCC cells to escape from lipotoxicity to adapt to a lipid-rich environment, which is achieved through inhibiting the Src-mediated c-Jun NH2-terminal kinase (JNK) activation. 46 Furthermore, oleoyl carnitine (AC18:1), the long-chain acylcarnitine that accumulates through FAO suppression induced by CPT2 down-regulation, enhances hepatocarcinogenesis through the signal transducer and activator of transcription 3 (STAT3)-mediated acquisition of stem cell properties. 9, 46 On the other hand, peroxisome proliferator-activated receptors (PPARs) are reported to be involved in regulating mitochondrial metabolism in liver within the disease context from NASH to HCC. The altered PPARs expression mainly induces mitochondrial metabolic dysfunctions, which can suppress FA oxidation, accumulate reactive oxygen species (ROS), and promote of lipogenesis. 47 The above evidence demonstrates that concomitant liver diseases may affect lipid metabolism and further promote tumour progression. the amount of lipases penetrating into lipid droplet, or inhibiting the enzymatic activity through activating CDC42 and PPARγ, which further aggravated the inflammatory reaction and eventually led to HCC. On the other hand, the HBx-depressed miR-205 and miR-384, are elaborated to be responsible for the abnormal lipid metabolism through accumulating cholesterol and mediating de novo lipid synthesis in HCC cells. [53] [54] [55] In another model, the HBx-induced lipogenesis and HCC development may also involve the Ras family oncogene Rab18, and its expression can be up-regulated by pathways related to COX-2 and miR-429, thus increasing the lipid anabolism. 56 However, HBx is also reported to promote HCC survival through inducing FAO and increasing the intracellular ATP and NADOH levels, and this can induce the resistance to glucose deprivation through activating the AMPK and FAO pathways in HCC cells. 57, 58 In terms of HCV-related HCC, the HCV core protein has been reported to play a vital part in enhancing the transcriptional activ- 
| INFLUEN CE OF HEPATITIS VIRUS E S ON H CC DE VELOPMENT
| LIPID ME TABOLIC REPROG R AMMING OF IMMUNO C Y TE S IN H CC
The role of lipid metabolism in regulating immune cells has recently aroused general concerns. Evidence collected in several types of solid tumours indicated the importance of tumour immunometabolic reprogramming and suggested a novel and crucial area for future research of liver cancer. 48 The complicated crosstalk between meta-
bolically reprogrammed immune cells and liver cancer cells has been
suggested, but the molecular mechanisms need further exploration ( Figure 4 ).
| Tumour-associated macrophages
Macrophages are the versatile innate immunocytes, which contribute to diverse situations, including host defence, homeostasis and pathology. They can be induced to the M1 and M2 phenotypes according to the surrounding microenvironment. The former is pro-inflammatory and polarized by either lipopolysaccharide (LPS) alone or in combination with Th1 cytokines, like IFN-γ and GM-CSF, and it is characterized by the production of inflammatory cytokines, tumour necrosis factor (TNF), reactive nitrogen and oxygen intermediates, and microbicidal functions. By contrast, the latter is anti-inflammatory and immunoregulatory, which can be polarized by Th2 cytokines like interleukin 4 (IL-4) and IL-13, and produce the release of anti-inflammatory cytokines, such as IL-10 and TGF-β. 66, 67 In a tumour setting, macrophages undergo changes in their lipid profile. Among them, tumour-associated macrophages (TAMs) are the predominant M2 phenotype in solid cancers including HCC. 68 Zhang et al had utilized an in vitro model to mimic the TAM-HCC interaction in TME, and their results suggested that the M2 monocyte-derived macrophages (MDMs) promoted HCC cell migration in an FAO-dependent manner by enhancing IL-1β secretion. Besides, they further put forward that IL-1β induction was ROS and pyrin domain-containing 3 (NLRP3)-dependent. 69, 70 Previous study also demonstrated that FA was consumed in the M2-like TAMs resulted from the IL4-driven activation of signal transducer and activator of transcription 6 (STAT6) and PPARG coactivator 1 beta (PPARGC1B), which peaked with the increases in mitochondrial biogenesis and epigenetic reprogramming towards FAO. 71 Besides, triacylglycerol (TAG) uptake was also found to be essential for FAO in M2 macrophages, which was orchestrated by PPAR and liver-X-receptor (LXR). 72, 73 In addition, apparently at odds with the increased FAO utilization, some TAMs accumulate intracellular lipids, which support not only their metabolic fitness, but also their immunomodulatory functions. Moreover, it has also been demonstrated that lipid loading of macrophages is associated with increased tumoricidal and F I G U R E 4 Lipid reprogramming in the tumour microenvironment affects the anti-/pro-tumoral functions of immune cells. Different immune cells in the TME of HCC exhibit different lipid metabolism changes, which affect their functions. These metabolically reprogrammed immune cells then have a differed influence on the liver cancer cells compared to the original immune cells. FAO, Fatty acid oxidation; HCC, Hepatocellular carcinoma; TME, tumour microenvironment inflammatory capacities. 71, 74 Likewise, fatty acid synthesis (FAS) enzymes are up-regulated in M2-polarized macrophages, and the de novo synthesized FAs are at least partially used to feed back into FAO. 73, 75 As for the murine peritoneal macrophages, an increased intracellular lipid content was shown to be linked with an enhanced cytotoxic activity, especially in those that were artificially enriched in polyunsaturated FA relative to those enriched in cholesterol. 74 In another study, the FAS expression in TAMs is suggested to polarize these cells to an IL-10-expressing pro-tumour phenotype. 76 In addition, the E-FABP-expressing TAMs are also reported to produce the high levels of IFN-β, which is essential for recruiting natural killer (NK) cells and anti-tumour activity through up-regulating the formation of lipid droplets (LDs). 74, 77 Nevertheless, accumulation of TAMs in HCC is linked with dismal prognosis. 78 Importantly, these macrophages express the immune checkpoint protein programmed cell death-ligand 1 (PD-L1), together with other immunosuppressive signals, like Toll-like receptor 4 (TLR4) and CD48/2B4, which inactivate the CD8 + T cells, promote the recruitment of regulatory T cells (Tregs) and suppress the activity of NK cells, thereby affecting local immunity. [79] [80] [81] [82] More studies should be performed on the effect of abnormal lipid metabolism of TAM on its immune function and tumour progression in HCC.
| T cells in TME
Recent studies have established that metabolic restrains, such as glucose restriction, impair the activities of effector T cells in TME. 69, 83 In the same context, the remarkable expansion of acti- FAs content plays a crucial part in the levels of FAO and oxidative phosphorylation in cells, among which the former is a keyway for immunocytes to produce ATP. 87, 88 Lipids are known to be the essential materials for cells, and their depletion in CD8 + T cells dramatically inhibits cell proliferation and signal transduction, which partly explains the lower number of CD8 + T cells in HCC than in adjacent tissues.
In terms of the related mechanism, the above-mentioned abnormal FAs metabolism in CD8 + T cells may be related to the inactivation of the SREBP pathway. 89 Moreover, SREBP deficiency hinders the metabolic reprogramming towards a glycolytic phenotype, which is typical for T-cell activation. Alternatively, Treg cells, which activate AMP-activated protein kinase and mainly rely on FAO rather than glycolysis, can survive under the amino acid and nutrient depletion conditions induced by the high glycolytic activity of proliferating tumour cells coupled with the poor vasculature within HCC, thereby exerting their immunosuppressive effects. 7, 90, 91 As indicated in open literature sources, the advantage of Tregs over conventional T cells (Tconvs) in TME may be dependent on the capacity of Tregs cells to compete for glucose and perform FAS and FAO at the higher rates than those of Tconvs. Additionally, it is proposed that FAS, rather than FA uptake, shapes the lipid Treg pool and contributes to Treg proliferation, after considering the high neutral lipid content and the metabolite signature observed in tumour bed Tregs. 83, 92, 93 Furthermore, Kalathil et al 94 pointed out that the frequency of expression of intracellular glycoprotein A repetitions predominant (GARP) and CTLA-4 in CD4 + Foxp3 + Tregs was also markedly increased among HCC patients compared with that in controls.
However, CTLA-4 inhibits glycolysis without augmenting FAO, suggesting that CTLA-4 sustains the metabolic profile of non-activated cells, which potentially indicates that CTLA-4 makes no contribution to the increase in FAO in tumour-associated Tregs. 95 Meanwhile,
Treg cells also express PD-1, which promotes the FAO of endogenous lipids through up-regulating CPT1A expression and inducing lipolysis, as indicated by the elevated levels of lipase adipocyte triglyceride lipase (ATGL), the lipolysis marker glycerol and the release of FAs. 95, 96 However, PD1 expression level in HCC-related Tregs should be further investigated. Moreover, it is also suggested in research that the frequency of PD-1 + CD4 + T cells and PD-1 expression levels in HCC patients are evidently higher than in healthy donors, which potentially implies that the above-mentioned PD1 regulation of FAO may be reflected in such cells. 94 On the other hand, natural killer T (NKT) cells, which share characteristics with both adaptive and innate immune cells and have multiple immunoregulatory roles, are CD1d restricted T cells that mostly recognize lipid antigens. 97 Since NKT cells mostly recognize lipid antigens, an altered tumour lipid metabolic profile will also alter the repertoire of lipid antigens that can potentially affect their immune-modulatory function. 98 One study in an obese 
| Tumour-associated dendritic cells
Dendritic cells (DCs) are the professional antigen-presenting cells (APCs), which bridge innate immunity with the adaptive one. DCs from HCC patients have an impaired ability to trigger immune response, in the meantime of promoting immunosuppression. 103 Modulating the lipid metabolism, such as de novo FAS during DCs activation, affects endoplasmic reticulum (ER) and Golgi expansion, thereby impacting their antigen-presenting ability. 104 In a setting of HCC, the tumour-associated dendritic cells (TADCs) express the scavenging receptor, such as macrophage scavenger receptor 1(MSR1) that facilitates lipid uptake and accumulation, which seems to support the immunogenic immune responses and cross-presentation. However, it in turn leads to the low expression of co-stimulatory molecules and DCs-related cytokines, as well as the decreased ability to effectively stimulate the allogeneic T cells of TADCs. 105, 106 Interestingly, Herber et al 105 resulted in the susceptibility to sorafenib-induced hand-foot skin reaction (HFSR), which had revealed the novel candidate biomarkers.
| Other immune cells
| PER S PEC TIVE S OF H CC THER APY FROM LIPID ME TABOLIC REPROG R AMMING
In summary, abnormal lipid can potentially serve as a biomarker for diagnosing HCC.
As mentioned above, some HCC cells and immune cells recruited
from TME meet their demands for energy and building materials by up-regulating the FAS, which have led the researchers to target key lipogenic enzymes, particularly FASN, or related metabolites, to slow down tumour growth. 116 For instance, TVB-2640, the latest orally available FASN inhibitor, is currently used in clinical trials to treat HCC. 117 Nonetheless, several first-generation FASN inhibitors exhibit strong toxicity in preclinical and clinical trials; therefore, targeting histone deacetylase 3 (HDAC3) may provide a new strategy to target FASN. 118 Noteworthily, Fasn ablation markedly delays but not prevents hepatocarcinogenesis in mice, whereas the concomitant inhibition of FASN-mediated FAS and hydroxy-3-methyl-glutaryl-CoA (HMg-CoA) reductase (HMGCR)-driven cholesterol production is highly detrimental for HCC cell growth in culture. 119 In addition, some studies report that the increased SCD activity promotes hepatocarcinogenesis through accumulating monounsaturated fatty acids (MUFAs) and activating the unfolded protein response via the ER stress related to sorafenib resistance in HCC. In addition, the researchers believe that SCD inhibition may reshift the balance of FA composition towards saturation, which exert a synergistic effect on HCC with sorafenib. 120 Besides, inhibition of FAO by etomoxir or other methods (such as targeted delivery of CPT1A siRNA/shRNA) may limit the immunosuppressive function of M2 macrophages, which may be developed as an effective therapeutic strategy. 48 Some immunotherapies related to lipid metabolism for cancers were summarized in Table 2 . Nonetheless, in consideration of the genotypic and tumour-biological diversities of HCC patients, as well as the complex lipid metabolism, therapeutic strategies targeting the FArelated pathways against HCC still lag behind.
| CON CLUS IONS
Our understandings towards the lipid metabolic changes in HCC development have been improved remarkably over the past years.
Nevertheless, the impacts of dysregulated FAs metabolism on HCC cells and the TME remains incompletely known So far here, the characteristics of lipid metabolism in HCC cells and surrounding immune cells are summarized, with the focus on the FA synthesis, oxidation and uptake pathways. Typically, the complicated lipid metabolic network, which regulates various functions of immunocytes, can either be functionally oriented or environmentally adapted; nonetheless, the two can together lead to immune microenvironment homeostasis, which affects HCC progression.
These observations suggest that lipid metabolic reprogramming constitutes an essential part for the tumorigenicity of these cells, which may be critical for cancer stem cells, particularly during the HCC initiation and invasion processes. In future research, clinical development of miRNA therapeutics should be concerned. For instance, an miRNA specifically targeting miR-33a/b, which plays a regulatory role in cellular cholesterol transportation, can increase circulation level of high-density lipoproteins (HDL)-cholesterol by enhancing randomized controlled trial (RCT) to the plasma, liver and faeces, and reduced plaque size and lipid content in mice. [121] [122] [123] More attention should be paid to miRNA therapeutics for HCC with aberrant lipid metabolism. Afterwards, as we mentioned above, studies on exogenous lipid uptake and transport should also be further carried out to obtain new therapeutic targets in an HCC setting. In addition, the mTOR pathway may be a suitable target to regulate immune cells by manipulating cellular lipid metabolism. Inhibition of mTOR by rapamycin can block the development of macrophages and CD4 + T cells in several scenarios, including liver cancer. 124, 125 Future studies can make efforts to combine immunity and lipid metabolism, so as to develop novel therapeutic methods that can benefit patients with HCC.
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